Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029089 (
ophthalmoplegia
)
3,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prognosis in
prostate cancer
is determined, in greater part, by the presence of metastases. Bone metastases can occur in any part of the skeleton even, for example, at the base of the skull. We present a case of a 78 year old male who, in December 2001, presented with paralysis of the third cranial nerve. The NMR and CAT scans were normal and circulating levels of PSA were elevated. He was referred to the Urology Service where the treatment guidelines included complete androgen block. Subsequently, he developed retro-orbital pain, divergent strabismus and palpebral ptosis. CAT and NMR indicated a soft tissue mass at the sphenoid level. Treatment was Gamma Knife Radio-surgery. Since August 2004, in conjunction with the latest rise in PSA, the patients general status deteriorated considerably and he was referred to the Oncology Service. There was an increase in the paralysis of the third, fourth and sixth cranial nerve (complete left
ophthalmoplegia
) and left-central facial paralysis. Metastases from
prostate cancer
can be disseminated via the lymphatic or the blood system. Currently, there are more metastases from large-size tumours. Metastases are critical in
prostate cancer
because of their adverse effect on the patients survival. Measurements of circulating levels of prostate specific antigen and prostate acid phosphatase are very useful in the clinical diagnosis of the primary tumour, or its metastases.
...
PMID:[Ophthalmoplegia in a patient with prostate cancer and bone metastases]. 1623 78
We report the case of a 60 year old male who complained of headache and blurry vision--that progressed to left
ophthalmoplegia
and ptosis--after receiving a dose of leuprolide for
Prostate cancer
therapy. Imaging showed a hemorrhagic sellar mass. The patient underwent transsphenoidal debulking, and the tissue obtained demonstrated immunohistochemical staining for LH. A literature review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for
prostate cancer
. In most cases, the sellar tissues stained for LH, consistent with a gonadotropinoma. The pathophysiology of these events is unclear, but recent animal models suggest possible explanations. The predominance of gonadotropinomas is important because they do not usually present with hypersecretory symptoms. Particular attention to clinical findings suggestive of a non functioning pituitary tumor in patients receiving GnRH agonist therapy is critical as routine screening with MRI is not practical.
...
PMID:Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. 1984 40
We report a case of a 68-year-old man with classical triad,
ophthalmoplegia
, ataxia and areflexia in uncommon context. Our patient presented initial symptoms during radiation therapy for
prostate cancer
. After elimination of brainstem stroke and carcinomatous meningitidis by his general physician, he was referred with a provisional diagnosis of Miller-Fisher syndrome (MFS). The main characteristics of this case of MFS were uncommon: antecedent illness of urinary tract infections by Pseudomonas aeruginosa, presence of high titres of IgG antibodies directed against Mycoplasma pneumoniae, CSF pleocytosis and intrathecal IgG synthesis, serum and CSF monoclonal IgG in a monoclonal gammopathy of undetermined significance (MGUS). The serum and CSF immunological marker of MFS was a monoclonal IgG antibody targeting the ganglioside GQ1b with abundant expression on oculomotor nerves.
...
PMID:[Miller-Fisher syndrome associated with monoclonal IgG lambda antibodies against ganglioside GQ1b]. 2047 81
We present the first Asian case of a 77-year-old man who developed pituitary apoplexy (PA) soon after gonadotropin-releasing hormone agonist (GnRHa) (leuprorelin) injection to treat
prostate cancer
. Headache,
ophthalmoplegia
, visual field deficit, nausea, and vomiting are the typical characteristics of pituitary apoplexy. Though the occurrence rate is rare, the consequence of this condition can vary from mild symptoms such as headache to life-threatening scenarios like conscious change. Magnetic resonance imaging is the best imaging modality to detect PA and sublabial trans-sphenoid pituitary tumor removal can resolve most of PA symptoms and is so far the best solution in consensus. We also review 11 previous reported cases receiving GnRHa for androgen deprivation therapy of
prostate cancer
, and hope to alert clinicians to use GnRHa with caution.
...
PMID:Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case. 2408 91
An elderly man presented to the acute ear, nose and throat (ENT) services with a history of intermittent, self-limiting facial nerve palsy. Full ENT examination was normal, with all cranial nerves and peripheral neurology intact. Multiple imaging modalities suggested an aggressive bony lesion, secondary to locally advanced prostate malignancy with extensive metastatic infiltration.
Prostate cancer
is known to preferentially metastasise to bone and has been known to cause multiple cranial nerve palsies and
ophthalmoplegia
. This is the first case described in the literature of metastatic
prostate cancer
presenting with intermittent facial nerve palsy.
...
PMID:The truth is in the water: metastatic prostate cancer presenting as an intermittent facial nerve palsy. 2591 61